SFX by Ex Libris Inc.

Title:	Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
Source:	Nature [0028-0836] Gao, M yr:2010

Basic

Full text

Full text available via Nature

Year:

Volume:

Issue:

Start Page:

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Guedj, J. "Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life." Proceedings of the National Academy of Sciences of the United States of America 110.10 (2013): 3991-3996.
description	2.	Wood, Nicholas W. "Dissection of the genetics of Parkinson's disease identifies an additional association 5' of SNCA and multiple associated haplotypes at 17q21." Human molecular genetics 20.2 (2010): 345-353.
description	3.	Pastor, F. "Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay." Nature 465.7295 (2010): 227-230.
description	4.	Lanford, Robert E. "Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection." Science 327.5962 (2010): 198-201.
description	5.	"Abstracts of the XVIII International HIV Drug Resistance Workshop: Basic Principles and Clinical Implications, June 9-13, 2009, Fort Myers, Florida, USA." Antiviral therapy 14.4 (2009).
description	6.	Chayama, H. "Pharmacokinetics, efficacy and safety of daclatasvir plus asunaprevir in dialysis patients with chronic hepatitis C: pilot study." Journal of viral hepatitis 23.11 (2016): 850-856.
description	7.	Aghemo, A. "Daclatasvir: a team player rather than a prima donna in the treatment of hepatitis C." Gut 64.6 (2015): 860-2.
description	8.	Cada, J. "Sofosbuvir." Hospital pharmacy 49.5 (2014): 466-78.
description	9.	Martin, Danyelle N. "Identification of transferrin receptor 1 as a hepatitis C virus entry factor." Proceedings of the National Academy of Sciences of the United States of America 110.26 (2013): 10777-10782.
description	10.	Rotman, Y. "Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C." Gut 63.1 (2013): 161-169.
description	11.	Sarasin-Filipowicz, Magdalena a. "Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy." Nature medicine 15.1 (2009): 31-3.
description	12.	Ebert, Margaret S S. "MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells." Nature methods 4.9 (2007): 721-726.
description	13.	"Report from the 4th International Workshop on Clinical Pharmacology of HIV Therapy. Atazanavir--booster of the future?" Treatmentupdate 15.3 (2003): 5-.
description	14.	Stevens, J. C. C. "Familial Alzheimer's disease and inherited prion disease in the UK are poorly ascertained." Journal of neurology, neurosurgery and psychiatry 82.9 (2010): 1054-1057.
description	15.	Kehagia, A. "Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease." Lancet neurology 9.12 (2010): 1200-1213.
description	16.	Smith, L. "NanotechnologyMolecular robots on the move." Nature 465.7295 (2010): 167-168.
description	17.	Ribas, A. "Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles." Nature advance online publication.7291 (2010): 1067-1070.
description	18.	Edwards, Todd L. "Genome-Wide Association Study Confirms SNPs in SNCA and the MAPT Region as Common Risk Factors for Parkinson Disease." Annals of human genetics 74.2 (2010): 97-109.
description	19.	Gu, W. "Distinct Argonaute-Mediated 22G-RNA Pathways Direct Genome Surveillance in the C. elegans Germline." Molecular cell 36.2 (2009): 231-244.
description	20.	"Cancer drug development: Targeted tumour take-out." Nature 462.7276 (2009): 961-961.